Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.

Leyre Riancho-ZarrabeitiaVictor Martínez-TaboadaÍñigo Rúa-FigueroaFernando AlonsoMaría Galindo-IzquierdoJuan OvallesAlejandro Olivé-MarquésAntonio Fernández-NebroJaime Calvo-AlénRaúl Menor-AlmagroEva Tomero-MurielEsther Uriarte-IsacelayaAlina BotenauMariano AndresMercedes Freire-GonzálezGregorio Santos SolerEsther Ruiz-LuceaMónica Ibáñez-BarcelóIván CastellvíCarlos GalisteoVíctor Quevedo VilaEnrique RayaJavier Narváez-GarcíaLorena ExpósitoJosé A Hernández-BeriaínLoreto HorcadaElena AurrecoecheaJose M Pego-Reigosa

Published in: Lupus (2020)

SLE-APS patients exhibited more severe clinical profiles with higher frequencies of major organ involvement, greater damage accrual and higher mortality than SLE-aPL and SLE patients.

Keyphrases

systemic lupus erythematosus
end stage renal disease
newly diagnosed
disease activity
early onset
cardiovascular disease
type diabetes